PAVmed Inc. shares a comprehensive business update and financial results for Q1 2026, highlighting advancements in medical technology and strategic engagement with key partners.

Reported Wednesday, Dec 31 - 7:50pm EST (TheFly subscription required to read more.)

Click to view the official SEC document.

Reported Thursday, Aug 27 - 7:43am EDT (TheFly subscription required to read more.)

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

PAVmed Inc. highlights significant business advancements and financial outcomes for the second quarter of 2026, showcasing promising growth across its subsidiaries.

PAVmed (NASDAQ: PAVM) reported a second-quarter 2026 business update covering its subsidiaries Lucid Diagnostics (NASDAQ: LUCD), Veris Health and Octeris Medical, along with financial results for the quarter ended June 30, 2026.Veris increased patient onboarding as its commercial engagement with OSU-The James advanced and continued development of its implantable physiological monitor toward a planned early 2027 FDA 510(k) submission. Lucid recognized $1.5 million in EsoGuard revenue on 2,770 tests, secured its first laboratory benefit manager coverage policy deeming EsoGuard medically necessary for eligible patients, and developed a cost-effectiveness model to support payor discussions.PAVmed highlighted PortIO first-in-human data showing 100% device patency, 90% completion of intended implant duration and no device-related adverse events, and ongoing FDA pre-submission work. Octeris advanced its multimodal endoscopic imaging probe toward clinical validation. For Q2 2026, PAVmed reported revenue of $33,000, operating expenses of $7.1 million, GAAP net loss attributable to common stockholders of approximately $5.5 million (or $(0.87) per diluted share), non-GAAP adjusted loss of $1.7 million, and cash of $3.8 million as of June 30, 2026.

Veris Health accelerated its commercial engagement with OSU-The James Veris Health implantable physiological monitor achieved development milestones towards upcoming FDA submission Lucid Diagnostics secured first laboratory benefit manager coverage policy for EsoGuard ® Conference call...

Lucid Diagnostics (Nasdaq: LUCD), a subsidiary of PAVmed (Nasdaq: PAVM), announced that Concert, a healthcare technology company recently acquired by Lyric, issued a positive commercial coverage policy effective July 2026 for non-invasive screening of esophageal precancer and cancer.The policy cites sufficient evidence in guidelines and peer-reviewed literature to demonstrate improved health outcomes and deems Lucid’s EsoGuard Esophageal DNA Test medically necessary for patients who meet American College of Gastroenterology (ACG) screening criteria. According to Lucid, multiple Concert client health plans have already adopted this policy, supporting broader commercial access to EsoGuard and reinforcing the company’s clinical evidence base.

NEW YORK, Aug. 4, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that management will participate in the following...

Conference Call and Webcast at 8:30 AM ET NEW YORK, July 31, 2026 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced...

Conference Call and Webcast at 8:30 AM ET NEW YORK, July 30, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will...

Reported Thursday, Jul 16 - 9:45am EDT (TheFly subscription required to read more.)

Reported Thursday, Jul 16 - 9:40am EDT (TheFly subscription required to read more.)

PAVmed (NASDAQ:PAVM – Get Free Report) and TELA Bio (NASDAQ:TELA – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership and dividends. Analyst Ratings This is a summary of current […]

PAVmed Non-GAAP EPS of -$0.16 beats by $0.13, revenue of $0.83M beats by $0.82M